PRTODAY / NewswireToday Free press release distribution service network

More news: Health/Surgery
Written by / Agency / Source: General Electric Company

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

GE Healthcare Exercises Option to Geronís Cellular Assay Patents - Agreement covers intellectual property relating to stem cell-based technologies for drug discovery and predictive toxicity screening
GE Healthcare Exercises Option to Geronís Cellular Assay Patents

 

NewswireToday - /newswire/ - Chalfont St. Giles, United Kingdom, 2012/10/08 - Agreement covers intellectual property relating to stem cell-based technologies for drug discovery and predictive toxicity screening . NYSE: GE

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Health/Surgery Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

GE Healthcare, the healthcare business of GE (NYSE: GE), announced today that it has expanded its 2009 license agreement with Geron Corporation for the development of cellular assays and models derived from embryonic stem cells (ESCís) for use in drug discovery and toxicity screening. Under the terms of the expanded license, GE Healthcare obtains exclusive global rights to Geronís intellectual property and know-how for the development and sale of cellular assays derived from induced pluripotent stem cells (iPS). Financial terms were not disclosed.

GE Healthcare is pioneering the development of human cell-based assays and models for use in drug discovery and predictive toxicity screening. As the worldwide pharmaceutical industry seeks to reduce the cost of drug development and to bring more effective, safer drugs to market, the availability of more biologically relevant and predictive cell models is becoming increasingly important. In 2010 the company launched CytivaTM cardiomyocytes (human heart cells), stem cell-based assays that are already helping pharmaceutical companies develop safer medicines by identifying - much earlier in the discovery process - drug candidates that show toxic effects. The company also plans to launch Cytiva hepatocytes (liver cells) for toxicity testing, and recently announced a collaboration with the Beijing Genomic Institute aimed at understanding the underlying genetic variation between ethnically diverse stem cell lines.

Dr Amr Abid, General Manager, Cell Technologies, GE Healthcare Life Sciences said,ďExpanding our agreement with Geron is a significant step forward and will help us realise our vision of bringing the benefits of stem cell derived assays and models to pharmaceutical and cell science research. In the immediate term it will allow us to accelerate the development of new technologies and products for our customers in drug discovery. Longer term, by taking a licence from GE Healthcare, the wider industry will also benefit from the ability to use key intellectual property without violating patent rights. This clarity and freedom to operate will, I believe, do much to advance the use of stem cell based assays in drug discovery.Ē

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Health/Surgery Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: General Electric Company

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 
 
  Your Banner Ad showing on ALL
Health/Surgery articles,
CATCH Visitors via Your Competitors Announcements!


GE Healthcare Exercises Option to Geronís Cellular Assay Patents

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

GE News Center |
Publisher Contact: Dr Val Jones - GE Healthcare 
+44(0)14 9449 8052 / +44(0)79 1717 5192 (mobile) val.jones[.]ge.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any General Electric Company securities in any jurisdiction including any other companies listed or named in this release.

Health/Surgery via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From General Electric Company / Company Profile


Read Health/Surgery Most Recent Related Newswires:

Bionic Prosthetics Manufacturers Drive R&D Initiatives across Emerging Markets to Impel its Adoption
Frost & Sullivan Acclaims CGIís Advanced Genomic & Biomarker Technologies That Drive Industry Innovation in Support of Precision Cancer Treatment
Frost & Sullivan Honors Linguamatics for Developing a Best-in-Class NLP-based Data Mining Platform for the Healthcare Industry
Therapist Launches Podcast to Reach Larger Audience
Top Innovative Health and Wellness Technologies to Accelerate Global Adoption of Precision Medicine Finds Frost & Sullivan
Rheumatoid Arthritis Diagnosis Tests Market Size to Expand At 6.2% CAGR through 2022 Says PMR
Persistence Market Research Publishes Health Information Exchange Market Opportunities and Forecasts 2017-2025
Persistence Market Research Publishes Microtome Cryostat Equipment Market Opportunities and Forecasts, 2017-2025
North America to Account for 4.3% CAGR in Global Hip Replacement Market Reports Persistence Market Research
HPMC Capsules Market to Register 10.9% CAGR During 2017-2025 Finds Persistence Market Research
Persistence Market Research Publishes Blood Thinner Market Opportunities and Forecasts 2017-2025
Occupational Medicine Market Estimated to Expand At A Robust CAGR Over 2025 Notes PMR
Persistence Market Research Publishes Traditional Chinese Medicine Market Forecast Over 2017-2025
Inferior Vena Cava Filters Market to Register A Strong Growth by 2025 Notes Persistence Market Research
Plasma Component Separator Market Set to Surge Significantly During 2017-2025 Says PMR

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  MagLar, Inc.

Visit  JobsWare.com





 
  ©2017 Newswire Today ó Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)